One of the hallmarks of Alzheimer’s disease (AD) is the accumulation of protein fragments called β-amyloid (Aβ) into plaques in the brain.
Current thinking is that soluble forms of this protein, called soluble oligomers, are toxic to neurons and are one of the root causes of brain deterioration in AD. This protein fragment is made through the cutting of a larger protein called amyloid precursor protein (APP) by two enzymes, BACE and γ-secretase.
Inhibition of the BACE enzyme halts the production of this toxic Aβ and thus the formation of new soluble oligomers and plaque. The hope is that efficient inhibition of BACE will arrest the progression of AD. CoMentis has designed potent inhibitors of BACE that can penetrate the brain effectively. We are currently completely pre-clinical testing of these compounds and preparing for testing in human clinical trials.